$KRYS

5 stories mentioning KRYSUpdated just now

Every FINWIRES story that references KRYS, newest first.

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.6%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 6.8%, and Bristol Myers rose 0.4%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 1.7%.Krystal Biotech (KRYS) shares dropped 8.4% after its Q2 product revenue fell short of analysts' estimates.

$AZN$BMY$ITGR$KRYS$LNTH

Sectors4h ago

Sector Update: Healthcare

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Krystal Biotech (KRYS) shares dropped 8.3% after its Q2 product revenue fell short of analysts' estimates.

$KRYS

Wire4h ago

Update: Krystal Biotech Shares Fall After Q2 Product Revenue Miss

(Updates with the latest stock movement in the first paragraph and headline.)Krystal Biotech (KRYS) shares were down 8.2% in Monday trading after the company's Q2 product revenue fell short of analysts' estimate.The company reported Q2 net income Monday of $1.79 per diluted share, compared with $1.29 a year earlier.Three analysts surveyed by FactSet expected $1.62.Net product revenue for the quarter ended June 30 was $119.2 million, compared with $96 million a year earlier.Analysts expected $120.9 million.Price: $313.00, Change: $-28.12, Percent Change: -8.24%

$KRYS

Insider Trading56d ago

Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing

Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on June 04, 2026, sold 25,000 shares in Krystal Biotech (KRYS) for $7,702,984. Following the Form 4 filing with the SEC, Krishnan has control over a total of 1,590,253 common shares of the company, with 1,450,253 shares held directly and 140,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1711279/000129870926000009/xslF345X05/wk-form4_1780699113.xml

$KRYS

Wire80d ago

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

Krystal Biotech's (KRYS) beremagene geperpavec to treat wounds in patients with dystrophic epidermolysis bullosa has received approval from the UK's Medicines and Healthcare products Regulatory Agency for use from birth onward, the agency said in a Friday statement.The medication, which is available in the form of gel, demonstrated 67% complete healing rate in a study of 31 patients at six months, according to the statement.Dystrophic epidermolysis bullosa is a rare genetic condition characterized by fragile skin and recurrent wounds.Price: $308.93, Change: $-7.37, Percent Change: -2.33%

$KRYS

Track with the FINWIRES app suite

FolioX

Track KRYS in your portfolio

WheelAI

Analyze KRYS options with the wheel strategy

StockInsider

See market sentiment on KRYS